Lung cancer, primarily non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), is distinguished by its high prevalence and marked mortality rates. Traditional therapeutic approaches, encompassing chemotherapy, radiation, and targeted therapies, frequently show limited efficacy due to acquired resistance and notable side effects. The objective of this review is to introduce a fresh perspective on the therapeutic strategies for lung cancer, emphasizing interventions targeting the epigenetic alterations often seen in this malignancy. This review presents the most recent advancements in the field, focusing on both past and current clinical trials related to the modulation of methylation patterns using diverse molecular agents. Furthermore, an in-depth analysis of the challenges and advantages of these methylation-modifying drugs will be provided, assessing their efficacy as individual treatments and their potential for synergy when integrated with prevailing therapeutic regimens.
肺癌，主要包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC），以其高发病率和高死亡率而备受关注。传统的治疗方法，包括化疗、放疗和靶向治疗，常因获得性耐药和显著副作用而疗效有限。本综述旨在为肺癌治疗策略引入新的视角，重点关注针对该恶性肿瘤中常见的表观遗传学改变的干预措施。文章介绍了该领域的最新进展，聚焦于过去和当前利用不同分子制剂调节甲基化模式的临床试验。此外，本文还将深入分析这些甲基化修饰药物面临的挑战与优势，评估其作为单一疗法的有效性，以及它们与现行治疗方案结合时可能产生的协同增效潜力。
Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective
肿瘤(癌症)患者之家